Background Status epilepticus (SE) is a neurologic emergency with high morbidity and mortality. Delays in SE treatment are common in clinical practice and can be associated with poorer outcomes. Our goal was to determine whether the implementation of an SE alert protocol improves time to administration of a second-line antiseizure medication (ASM) in hospitalized adults.
antiseizure medication (ASM; i.e., a benzodiazepine) is typically followed by a second-line agent such as phenytoin/fosphenytoin, sodium valproate, levetiracetam, or phenobarbital. 4 A multicenter study found that late administration (>10 minutes) of first-line benzodiazepines in SE was independently associated with delayed administration of second-and third-line ASMs and with increased in-hospital mortality and morbidity (i.e., longer duration of convulsive seizures, increased need for continuous infusions, and more frequent hypotension). 3 In retrospective studies, late administration of a second-line ASM was associated with delayed return of consciousness and with poorer functional outcomes. 7, 8 More rapid seizure control has the potential of decreasing these adverse outcomes.
Despite the importance of timely management of SE, treatment delays occur commonly in clinical practice. In part because second-line ASMs need to be obtained from a central pharmacy, a previous quality improvement project in our institution found that the mean time to administration of a second-line ASM was 71 ± 11.8 minutes. 9 We found that these delays failed to improve after an educational program for residents, pharmacists, and nursing staff, or after the development of an electronic SE order set. 10 Due to several barriers, 11 substantial delays in SE treatment have also been reported from other institutions in the United States and Europe. 3, [12] [13] [14] In addition to the use of protocoldriven therapies, implementation of SE intervention teams is proposed as a strategy that may improve the timeliness of SE treatment.
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Initially developed as a quality improvement project, we hypothesized that implementation of an SE alert protocol could reduce delays in administration of a second-line ASM in hospitalized adults compared to usual care.
Methods
Standard protocol approvals, registrations, and patient consents This study was approved by the University of Kentucky Medical Center (UKMC) institutional review board (protocol #17-0555-P3K). The study met criteria for a Health Insurance Portability and Accountability Act waiver of authorization.
Study design
We developed an inpatient SE alert system, which was modeled after the stroke alert protocol used at UKMC. Whenever a patient admitted to the hospital or to the emergency department is suspected to have either convulsive or electrographic SE, 1 health care providers (including nurses, advanced practice providers, or physicians) can activate an SE alert by calling a single operator (Central Monitoring Station) who then simultaneously sends a text page to the general neurology and pharmacy residents, a rapid response team (RRT, also known as medical emergency team), and the responsible primary house officer. The message reads "Status epilepticus alert" and gives the patient's location. Neurology residents, pharmacy residents, and the RRT respond immediately to the patient's location. Responders then work collaboratively to coordinate the patient's emergent evaluation and treatment. The protocol workflow and the specific roles of each responder are described in the figure. The inpatient SE alert protocol became available at UKMC in March 2015. It is active 24 hours a day, 7 days per week.
In the present quasi-experimental cohort study, we compared the time to administration of a second-line ASM for hospitalized patients who were managed using the SE alert protocol vs a group of inpatients who were treated without the protocol (usual care). Our primary research question was "Is use of the SE alert protocol associated with shorter time to administration of a second-line ASM?" (Classification of Evidence Class III). We followed the Revised Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0). 15 
Patients
We included all patients aged 18-85 years who were managed at UKMC using the SE alert protocol between March 2015 and June 2017 (n = 19). These were identified using Central Monitoring Station records. As controls, we identified the first 20 consecutive patients treated for SE over the same time period who were managed using existing institutional practices (i.e., without SE alert) by reviewing 350 cases recorded in neurology consult logs. Because the SE alert protocol was used variably in the initial period of adoption, this allowed us to identify patients managed both with and without the SE alert system over the same time period. As this was an observational cohort study, a sample size calculation was not performed.
Data collection
Two of 3 neurology residents (M.F.V., J.L.C., K.S.D.) retrospectively abstracted data from each identified patient's electronic medical record using a standardized form. Any discrepancies were resolved by the third abstractor. Abstractors reviewed data for patients in the SE alert and the usual care groups; they were not masked to SE alert status. Data related to medication ordering/administration also were collected by at least 2 abstractors and were then verified by a pharmacist (A.M.C.).
Outcomes
The primary outcome was time to administration of secondline ASM (time between electronic order entry and ASM administration). The effect of the following variables on time to administration of second-line ASM was assessed: (1) responding neurology resident's level of training (postgraduate year 2, 3, or 4); (2) primary service at the time when a concern for SE was noted (emergency medicine, neurology, medical, or surgical); (3) patient location at the time when a concern for SE was noted (out of hospital, emergency department, hospital floor, intensive care unit [ICU]). Secondary outcomes included the need for intubation, administration of IV anesthetics, number of days in the ICU, number of days on mechanical ventilation, and all-cause mortality during the index hospitalization.
Statistical analysis
Statisticians (C.K., Y.X.) not involved with patient care analyzed de-identified patient data. Two-sample comparisons of continuous variables (expressed as mean ± SEM) were analyzed using t tests. For categorical variables, either χ 2 or Fisher exact tests were used depending on expected cell numbers in the contingency tables. The relationship between time to administration of second-line ASM and (1) residents' postgraduate year, (2) primary service at the time when a concern for SE was noted, and (3) patient location at the time when a concern for SE was noted was analyzed using one-way between-subject analysis of variance. For the primary study hypothesis, a p value <0.05 (one-sided) was considered significant. All other p values were 2-sided. Data analyses were conducted using SAS 9.4 (Cary, NC). There were no missing data.
Data availability
Anonymized data will be shared by request from any qualified investigator.
Results
Demographic and epilepsy-related characteristics were similar between the SE alert (n = 19) and the usual care (n = 20) groups (table 1) . Time to administration of the second-line ASM was shorter for patients managed using the SE alert (22.21 ± 3.44 minutes) compared to those who were managed without activation of the SE alert system (58.30 ± 6.72 minutes; p < 0.0001). There was no difference in time to administration of the second-line ASM between the SE alert and the control groups based on (1) The proportion of patients who were ultimately diagnosed with nonepileptic psychogenic SE was similar between the 2 groups. There were no differences between groups in the need for intubation, administration of IV anesthetics, number of days in ICU, number of days on mechanical ventilation, or all-cause mortality during the index hospitalization (table 2). Our SE alert was modeled after our existing stroke alert protocol.
Discussion
Our previous study conducted at UKMC in 2013, using the same definitions as in the current study, found that mean time to administration of a second-line ASM for patients in SE was 71 ± 11.8 minutes, 9 which did not differ from the delay found in the current study for patients treated without activation of the SE alert system (p = 0.3866). The SE alert protocol reduced time to administration of the second-line ASM across all groups analyzed. Therefore, the improvement in time to administration of a second-line ASM that was found in the SE alert group was likely due to the use of the SE alert protocol rather than secular changes in the rate of administration of second-line ASMs over time.
Because poor outcomes are associated with the duration of seizures, 3, 5, 6 time to administration of an adequately dosed ASM may have an important effect on morbidity and mortality. 3, 7 In the present study, we hypothesized that the introduction of an SE alert system would reduce treatment delays compared to standard prior practice. Our SE alert was modeled after our existing stroke alert protocol. Given that the vast majority of academic institutions and many community hospitals in the United States and other developed In our study population, the choice of the second-line ASM was guided by patient comorbidities and concomitant use of other ASMs.
countries currently have dedicated protocols for management of patients with suspected acute stroke, it may be feasible to adapt such protocols locally for the management of suspected SE. In our study, time to administration of a second-line ASM did not differ significantly based on neurology residents' level of training in either the intervention or the control groups, suggesting that very extensive physician training may not be essential for successful implementation of an SE alert protocol.
We modeled our SE alert protocol after our institution's stroke alert protocol, which also involves mobilization of a team including neurology and pharmacy residents and an RRT. Because delays in treatment of SE are associated with poor outcomes, early treatment is imperative. In comparison to the lack of effect of other approaches we had used to optimize treatment of SE patients (including an educational program for residents, pharmacists, and nursing staff, and the development of an electronic SE order set), we found that the SE alert protocol led to earlier ASM administration. In this context, mobilization of resources is justified.
Although the SE alert system reduced time to administration of a second-line ASM, this did not affect our secondary outcomes. The study, however, was not powered to detect these effects, and the lack of a difference might be due to the relatively small sample size. Studies with larger numbers of patients are needed to determine the effect of an SE alert protocol on patient outcomes. Of note, however, the SE alert protocol did not lead to treating higher numbers of patients with nonepileptic psychogenic SE.
In our study population, the choice of the second-line ASM was guided by patient comorbidities and concomitant use of other ASMs. For example, certain drugs are best avoided in patients with liver or kidney disease. Nonetheless, it is difficult to determine clinical reasoning regarding drug choice based on medical record review. The focus of our initiative was to reduce the time of administration of the second-line ASM, regardless of the drug chosen.
The present study has limitations. The study was observational and we did not randomize patients to the SE alert protocol or to usual care. Although we found no systemic differences between patients who were vs were not treated under the protocol, there may have been unmeasured confounding. Based on our retrospective chart review, it was not possible to extract accurate information regarding seizure cessation times. The use of prospective data ascertainment or electronic methods for automated extraction of EEG data may be considered in future studies, as these methods may provide accurate and searchable information to address this question. Benzodiazepines, the first line treatment for SE, are readily available in our hospital's emergency department and in inpatient units. In urgent situations, they can be administered by nursing staff following a verbal order by the treating physician and be removed from the automated dispensing cabinet via override. In such cases, the order may be entered in our electronic medical record system some time later. As we could not reliably determine the time the first line drug was ordered or administered, we could not assess the time to its administration or its association with SE duration. Similarly, because the time of SE onset could not be reliably determined, we assessed the delay between when the second-line ASM was ordered to when it was administered.
Although abstractors were not masked to group, this would not affect this study's primary outcome. The ordering and administration times of ASM (the primary outcome of our study) are stored in the electronic medical record and cannot be modified. At least 2 abstractors independently retrieved this information. The data were then verified by a pharmacist to ensure accurate documentation. We also recorded hard outcomes (such as all-cause mortality, use of ventilatory support, use of IV anesthetics, and duration of ICU stay). The risk of bias in the data extraction should be negligible.
As this was not one of our study outcomes, we did not assess the effect of second-line ASM on SE resolution. Nevertheless, we did evaluate the need for IV anesthetics in SE patients, which can be closely related.
Classification of evidence
This study provides Class III evidence that for adult inpatients treated for SE, implementation of an SE alert protocol reduces time to administration of second-line ASM.
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